A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications
Jeontaik Kwon, Cara Staley, Megan McCullough, Selena Goss, Mariano Arosemena, Babak Abai, Dawn Salvatore, David Reiter, Paul DiMuzio, Jeontaik Kwon, Cara Staley, Megan McCullough, Selena Goss, Mariano Arosemena, Babak Abai, Dawn Salvatore, David Reiter, Paul DiMuzio
Abstract
Objective: Vascular groin incision complications contribute significantly to patients' morbidity and rising health care costs. Negative pressure therapy over the closed incision decreases the infection rate in cardiac and orthopedic procedures. This study prospectively evaluated negative pressure therapy as a means to decrease wound complications and associated health care costs.
Methods: This was a randomized, prospective, single-institution study of 119 femoral incisions closed primarily after elective vascular surgery including both inflow (eg, aortofemoral) and outflow (eg, femoral-popliteal bypass) procedures. Incisions were categorized as high risk for wound complications on the basis of body mass index >30 kg/m2, pannus, reoperation, prosthetic graft, poor nutrition, immunosuppression, or hemoglobin A1c >8% and randomized 1:1 to standard gauze (n = 60) dressing vs negative pressure therapy (Prevena [Acelity, San Antonio, Tex], n = 59). Wound complication rate, length of stay (LOS), reoperation, readmission, and variable hospital costs were determined during 30 days. Statistical analysis was performed using χ2 test along with a two-sample unpaired t-test for continuous variables.
Results: There were no significant demographic differences (age, sex, risk factors for wound complication) between the two high-risk groups. In low-risk controls, the major wound complication rate was 4.8% (involving one infection in 21 incisions), resulting in a 3.8-day LOS, 4.8% reoperation, 4.8% readmission rate, and $17,599 in average variable cost. For high-risk controls, there was a significant increase in major wound complications to 25% (including all 12 infections in 60 incisions), LOS (10.6 days), reoperation (18.3%), readmission (16.7%), and costs ($36,537). Finally, negative pressure therapy significantly reduced major wound complications to 8.5% (including five of six infections in 59 incisions; P < .001), reoperation (8.5%; P < .05), and readmission (6.8%; P < .04) but not LOS (10.6 days). The average variable cost was reduced ($30,492), yielding an average savings of $6045 per patient (P = .11).
Conclusions: This study suggests that negative pressure therapy significantly reduces the major wound complication, reoperation, and readmission rates for patients at high risk for groin wound complications. Furthermore, this therapy may lead to a reduction in hospital costs. Negative pressure therapy for all groin incisions considered at high risk for wound complications is recommended.
Trial registration: ClinicalTrials.gov NCT02581904.
Keywords: Negative pressure therapy; Vascular groin incision complications; Wound infection.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Source: PubMed
Közelgő klinikai vizsgálatok
-
Nicholas ButowskiSiren BiotechnologyMég nincs toborzásGlioma | Agyi neoplazma | Ismétlődő, magas fokú gliomákEgyesült Államok
-
State University of New York at BuffaloMég nincs toborzásBeteg bevonásaEgyesült Államok
-
Poitiers University HospitalMég nincs toborzás
-
Assistance Publique - Hôpitaux de ParisMég nincs toborzásSarlósejtes anaemia | Vaso-okkluzív válság
-
University of California, IrvineToborzásAgyrák | CNS rák | Idegrendszeri rák | Metasztatikus AgydaganatEgyesült Államok
-
Qualia Life SciencesToborzás
-
Guangdong Raynovent Biotech Co., LtdMég nincs toborzás
-
The Hong Kong Polytechnic UniversityWu Jieh Yee Charitable FoundationToborzásFelnőttek | Gyengelátó digitális asszisztens | LátászavarokHong Kong
-
Shanghai General Hospital, Shanghai Jiao Tong University...Még nincs toborzásHasnyálmirigy duktális adenokarcinóma (PDAC)
-
Sun Yat-sen UniversityMég nincs toborzásDohányzás abbahagyása | AI ügynök | Early-Stage Cancer
-
Affiliated Hospital of Nantong UniversityMég nincs toborzás
-
AIMEDBIOBoehringer IngelheimMég nincs toborzásSzilárd daganatokFranciaország, Japán, Dél -Korea, Egyesült Államok, Ausztrália